Questions: Vaccine Response, Immunogenicity, and Adjuvants

Question 1

Researchers inject mice with a purified recombinant protein antigen alone and observe a weak, short-lived antibody response. When the same antigen is formulated with alum adjuvant, the antibody response is substantially stronger and more durable. What is the best mechanistic explanation?

• A. Alum increases the dose of antigen delivered, so more B cells are activated
• B. Alum directly activates B cells, bypassing the need for T cell help
• C. A purified protein alone lacks the danger signals that normally accompany infection; alum activates inflammasomes and recruits dendritic cells, providing the co-stimulatory signals needed to drive robust adaptive immunity
• D. Alum prevents antigen degradation in the bloodstream, extending the time B cells are exposed to it

Answer: (C)

The adaptive immune system evolved to respond to infections, which arrive with molecular danger signals (PAMPs) that activate innate immune receptors. A purified protein stripped of these signals is recognized as antigen but fails to trigger the dendritic cell activation and co-stimulation needed for clonal expansion, affinity maturation, and memory formation. Alum works by forming a slow-release depot and activating the NLRP3 inflammasome, recruiting and maturing dendritic cells — the critical bridge between innate sensing and adaptive response. Without this 'danger context,' the immune system treats the antigen as non-threatening. Option A is wrong because alum doesn't increase antigen dose. Option D is partially true (depot effect) but misses the main mechanism.

Question 2

A vaccine developer wants to generate strong CD8+ cytotoxic T cell responses against an intracellular pathogen. Which vaccine platform and adjuvant combination is most likely to achieve this?

• A. An inactivated whole-pathogen vaccine with alum adjuvant, which drives strong Th2 responses
• B. A live-attenuated vaccine or a TLR agonist-containing adjuvant system, which activates dendritic cells to cross-present antigen via MHC class I and drive Th1/CD8+ responses
• C. A subunit protein vaccine with alum, which primarily generates CD8+ T cells through direct B cell activation
• D. An oral vaccine, which always generates stronger CD8+ responses than intramuscular injection

Answer: (B)

CD8+ cytotoxic T cells require antigen presentation via MHC class I, which is primarily loaded with peptides derived from intracellular protein synthesis. Live-attenuated vaccines replicate briefly inside cells, naturally entering the MHC class I pathway and generating CD8+ responses. TLR agonist adjuvants (like AS04's monophosphoryl lipid A) activate dendritic cells to cross-present exogenous antigen via MHC class I, also driving CD8+ responses and Th1 polarization — critical for intracellular pathogens. Alum primarily drives Th2 responses (antibodies), making it less suitable for generating cytotoxic T cell immunity. Inactivated vaccines primarily enter the MHC class II pathway, generating CD4+ T help and antibodies but weak CD8+ responses.

Question 3

Adjuvants enhance vaccine immunogenicity by mimicking molecular danger signals that normally accompany infection, rather than by tricking the immune system into an inappropriate response.

• T. True
• F. False

Answer: True

This is the correct mechanistic understanding. Adjuvants like alum activate pattern recognition receptors (inflammasomes, TLRs) and recruit dendritic cells — the same molecular pathways that are activated during genuine infection by pathogen-associated molecular patterns (PAMPs). The immune system evolved to require these danger signals as a 'second signal' for full activation, preventing responses to harmless antigens. Adjuvants provide this signal for vaccine antigens that lack it. Framing adjuvants as 'tricks' misrepresents the biology: they are pharmacological mimics of natural infection signals, providing the context the immune system needs to mount a protective response.

Question 4

Live-attenuated vaccines are generally superior to inactivated or subunit vaccines because they produce stronger immune responses across most dimensions.

• T. True
• F. False

Answer: False

Live-attenuated vaccines do generate broad responses — replication inside cells activates both MHC class I (CD8+ T cells) and class II (CD4+ T help and antibodies), producing comprehensive immunity. But they have real limitations: they cannot be used in immunocompromised individuals (risk of causing disease), they require cold chain maintenance, and they occasionally revert to virulence (as in rare cases with oral polio vaccine). Inactivated and subunit vaccines are safer for vulnerable populations and more stable, and with appropriate adjuvants and antigen design they can produce strong, durable protection. The optimal platform depends on the pathogen, target population, and immune response needed — there is no universally superior approach.

Question 5

Why do booster doses improve vaccine-induced immunity, and what biological processes do they drive that single-dose immunization may not fully complete?

Model answer: Booster doses drive additional rounds of affinity maturation in germinal centers, where B cells undergo somatic hypermutation and clonal selection for increasingly high-affinity antibody variants. Each round of germinal center reaction produces antibodies with better binding to the target antigen and expands the memory B and T cell pools. Repeated antigen exposure also promotes the generation of long-lived plasma cells that continuously secrete antibody for years. A single immunization may generate a peak antibody response that wanes as short-lived plasma cells die; boosters re-activate memory cells and generate longer-lived protective immunity. Timing matters because memory cells must be present and antigen must be re-encountered to trigger the superior secondary response.

Students often think vaccine schedules are arbitrary or about exposing the immune system to more antigen. The key insight is that booster doses are calibrated to the kinetics of germinal center reactions and memory formation — they exploit the biology of the secondary response (faster, higher-affinity, more durable) to build immunity that single exposures cannot achieve.